医学
可视模拟标度
Oswestry残疾指数
腰椎
临床试验
临床终点
外科
腰痛
不利影响
随机对照试验
最小临床重要差异
多中心研究
背痛
多中心试验
重复措施设计
麻醉
腰椎
随机化
置信区间
物理疗法
腰椎间盘突出症
安慰剂
入射(几何)
临床疗效
作者
Zhuoyun Wu,Shiyu Dong,马宏庆,Y Y,Kuayue Zhang,Xuehui Wang,Hao Wang,Shuangqing Du,Wenjie Wu,Tao Fan,Jian Wei,Wenge Wang,Yue Han,Chao Ma,Fuhong Cheng,Yuan Pang,Rongxin Sun,Ziqiang Zhu,Linlin Chen,Wei Fang
摘要
AIM: This study aimed to evaluate the efficacy and safety of OsteoKing compared to a standard active comparator (Yaobitong capsules) for managing lumbar disc herniation (LDH). METHODS: A randomized, double-blind, double-dummy, positive-controlled, multicenter trial was conducted across 17 hospitals in China. A total of 210 eligible patients with LDH were randomized in a 2:1 ratio to receive either OsteoKing (n = 140) or Yaobitong capsules (n = 70) for 4 weeks. The primary efficacy endpoint was the change in the Visual Analog Scale (VAS) score from baseline to week 4. Secondary endpoints included the Oswestry Disability Index score, the resolution rate of individual traditional Chinese medicine symptoms, and safety assessments. Missing data and repeated measures were handled using multiple imputation and a mixed-model for repeated measures. RESULTS: Baseline characteristics were well-matched between the two groups. At week 4, both groups experienced substantial improvements in pain and lumbar function. In the full analysis set (FAS), the between-group least squares mean difference (LSMD) in VAS reduction was -0.37 (95% CI: -0.77 to 0.03; p = 0.074). In the per-protocol set (PPS) analysis, the OsteoKing group achieved a significantly greater reduction in VAS scores compared to the control group (LSMD: -0.41, 95% CI: -0.82 to -0.01; p = 0.0453). Improvements in ODI scores were comparable between the groups in both the FAS and PPS analyses (p > 0.05). Additionally, the OsteoKing group demonstrated significantly higher resolution rates for low back pain and fatigue/lassitude at week 4 (p < 0.05). Both treatments were safe and well-tolerated, with comparable incidence rates of adverse events (21.43% vs. 24.29%, p = 0.6396). CONCLUSIONS: OsteoKing demonstrated comparable overall efficacy and safety to Yaobitong capsules in improving lumbar function and relieving symptoms in patients with LDH. Furthermore, OsteoKing may offer a modest, short-term analgesic advantage at the 4-week mark. OsteoKing represents a safe, effective, and viable conservative therapeutic option for LDH.
科研通智能强力驱动
Strongly Powered by AbleSci AI